Published: Vol 7, Iss 16, Aug 20, 2017 DOI: 10.21769/BioProtoc.2511 Views: 10104
Reviewed by: Ralph BottcherAnonymous reviewer(s)
Protocol Collections
Comprehensive collections of detailed, peer-reviewed protocols focusing on specific topics
Related protocols
Advances in Proximity Ligation in situ Hybridization (PLISH)
Monica Nagendran [...] Tushar J Desai
Nov 5, 2020 6077 Views
The Establishment of 3D Polarity-Reversed Organoids From Human Endometrial Tissue as a Model for Infection-Induced Endometritis
Xin Zhang [...] Zhaohui Liu
Jun 20, 2025 734 Views
Protocol for 3D Bioprinting a Co-culture Skin Model Using a Natural Fibrin-Based Bioink as an Infection Model
Giselle Y. Díaz [...] Stephanie M. Willerth
Jul 20, 2025 1912 Views
Abstract
Primary mammary tumor organoids grown in 3D are an excellent system to study tumor biology. They resemble the organization and physiology of native epithelia more closely than cancer cell lines grown in 2D, and additionally model interactions with the ECM (Boj et al., 2015; Clevers, 2016; Shamir and Ewald, 2014). Mammary tumor organoids are therefore a promising model system to identify and characterize novel drivers of breast cancer that would be unlikely to be identified using 2D cell lines. Antisense oligonucleotides can be used to efficiently and specifically knockdown target genes in the cell (Bennett et al., 2017). They can be taken up freely by organoids without the need for a transfection agent, making them a convenient tool for routine lab studies and screens.
Keywords: OrganoidsBackground
Breast cancer is the most frequent malignancy in women worldwide and the second leading cause of cancer mortality in women (Siegel et al., 2017). To improve existing treatment regimens, it is critical to identify and investigate new molecular targets that have the potential to prevent breast cancer progression. We applied RNA-seq to generate a comprehensive catalog of long non-coding RNAs (lncRNAs) that are dysregulated in primary mammary tumors compared to normal mammary epithelial cells and prioritized 30 previously uncharacterized lncRNAs as Mammary Tumor Associated RNAs (MaTARs). In order to functionally assess MaTARs as key drivers of tumor progression, we performed antisense oligonucleotide (ASO)-mediated knockdown assays of all 30 MaTARs in 3D mammary tumor organoids (Diermeier et al., 2016).
ASOs are short (20-mers), single stranded DNA molecules containing phosphorothioate-modified nucleotides as well as modifications of the 2’-ribose (5-10-5 2’-MOE gapmer) (Geary et al., 2015). Upon binding of the ASO to its complementary target, the RNA-DNA duplex stimulates degradation of the lncRNA by RNase H and thereby reduces the level of the respective transcript (Wu et al., 2004). Importantly, we found that ASO uptake in primary mammary tumor cells and organoids is efficient without the use of transfection agents, a mechanism that has been studied in detail in hepatocytes (Koller et al., 2011). ASO-mediated knockdown is particularly efficient for nuclear retained lncRNAs (Lennox and Behlke, 2016).
Organoids represent an ex vivo model of mammary gland development and model branching morphogenesis in 3D culture (Ewald, 2013; Fata et al., 2007), which is driven by two physiological processes: collective cell migration and cell proliferation. As the same processes also drive tumor invasion, the mammary organoid system can be utilized to model invasive breast cancer in vitro. Loss of branching was observed upon ASO-mediated knockdown of 20 MaTARs in organoids (Diermeier et al., 2016) as well as the lncRNA Malat1 (Arun et al., 2016), indicating that these RNAs are involved in mammary tumor cell proliferation and/or collective cell migration. Hence, we suggest that antisense-mediated knockdown in mammary tumor organoids can be used to identify and characterize novel drivers of tumor progression.
Materials and Reagents
Equipment
Procedure
Data analysis
Notes
Recipes
10x TaqMan RT buffer | 5 µl |
Random hexamers | 2.5 µl |
MgCl2 (25 mM) | 11 µl |
dNTPs | 10 µl |
RNase Inhibitor | 1 µl |
RTase | 1.25 µl |
Nuclease-free H2O | 8.25 µl |
Total volume | 39 µl |
PowerUp SYBR Green Master mix | 10 µl |
Nuclease-free H2O | 7 µl |
Total | 17 µl |
Primer mix (for + rev, 10 µM) | 1/well (conc.: 0.5 µM/well) |
Acknowledgments
Our tumor organoid protocol is based on previous work from Andrew Ewald’s lab (Ewald, 2013; Nguyen-Ngoc et al., 2015). The Manhasset Women’s Coalition Against Breast Cancer (S.D.D.) and the NCI 5P01CA013106-Project 3 (D.L.S.) supported this research.
References
Article Information
Copyright
© 2017 The Authors; exclusive licensee Bio-protocol LLC.
How to cite
Diermeier, S. and Spector, D. L. (2017). Antisense Oligonucleotide-mediated Knockdown in Mammary Tumor Organoids. Bio-protocol 7(16): e2511. DOI: 10.21769/BioProtoc.2511.
Category
Cancer Biology > General technique > Molecular biology technique
Molecular Biology > RNA > qRT-PCR
Cell Biology > Cell isolation and culture > 3D cell culture
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Tips for asking effective questions
+ Description
Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.
Share
Bluesky
X
Copy link